Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.
about
A physiologically-motivated compartment-based model of the effect of inhaled hypertonic saline on mucociliary clearance and liquid transport in cystic fibrosisAntiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC ModelsPotentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.Confidentiality in Biobanking Research: A Comparison of Donor and Nondonor Families' Understanding of Risks.An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.
P2860
Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development, clinical utility, ...... treatment of cystic fibrosis.
@en
Development, clinical utility, ...... treatment of cystic fibrosis.
@nl
type
label
Development, clinical utility, ...... treatment of cystic fibrosis.
@en
Development, clinical utility, ...... treatment of cystic fibrosis.
@nl
prefLabel
Development, clinical utility, ...... treatment of cystic fibrosis.
@en
Development, clinical utility, ...... treatment of cystic fibrosis.
@nl
P2860
P921
P356
P1476
Development, clinical utility, ...... treatment of cystic fibrosis.
@en
P2093
Heather E Elphick
Ruth O'Reilly
P2860
P304
P356
10.2147/DDDT.S30345
P407
P577
2013-08-30T00:00:00Z